Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs) for mental health conditions, announced that its CEO, Michael Halstead, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The conference, scheduled for September 14-16, 2026, in New York City, is a key event for investors and industry leaders. Halstead's presentation, set for September 14 at 9 a.m. EDT, will be webcast live and later available on the company's investor relations website.
This announcement is significant for several reasons. First, it provides a platform for Helus Pharma to communicate its strategic vision and clinical progress to a broad investment audience. The company is advancing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder (MDD), which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). Additionally, HLP004, another NSA, is in Phase 2 for generalized anxiety disorder (GAD). These programs target large unmet needs in mental health, where current treatments often fall short.
The potential implications of Helus Pharma's work are profound. Depression and anxiety affect millions worldwide, and existing therapies, such as SSRIs, can take weeks to show effects and may not work for all patients. Helus Pharma's NSAs are designed to activate serotonin pathways believed to promote neuroplasticity, potentially offering faster and more durable improvements. If successful, these treatments could transform the standard of care, providing relief to patients who have not responded to other interventions.
The company's participation in the H.C. Wainwright conference also highlights its growing visibility in the investment community. With a focus on innovative science and a robust pipeline, Helus Pharma is positioning itself as a leader in the emerging field of psychedelic-inspired therapeutics. The company operates in Canada, the United States, the United Kingdom, and Ireland, and continues to expand its research portfolio.
Investors and stakeholders will be keen to hear Halstead's insights on the company's development timelines, regulatory strategies, and potential market opportunities. The fireside chat format allows for a deeper exploration of these topics, providing clarity on how Helus Pharma plans to navigate the complex path from clinical trials to commercialization.
For those unable to attend the conference in person, the live webcast and replay offer an accessible way to stay informed. The company's investor relations website, accessible at https://ibn.fm/1HSIo, contains the full press release and will host the replay. This transparency is crucial for maintaining investor confidence and ensuring that all stakeholders have access to the same information.
In summary, Helus Pharma's CEO presentation at the H.C. Wainwright conference represents a key opportunity to showcase the company's progress and future direction. With its lead candidates in late-stage trials and a commitment to addressing mental health disorders, Helus Pharma is at the forefront of a potential paradigm shift in psychiatric treatment. The outcomes of its clinical programs could have significant implications for patients, healthcare providers, and investors alike.
